Activest Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$247 Sell
1
-21
-95% -$5.34K ﹤0.01% 958
2026
Q2
$6.62K Buy
22
+21
+2,100% +$6.33K ﹤0.01% 668
2026
Q1
$331 Sell
1
-107
-99% -$36.4K ﹤0.01% 1103
2025
Q4
$42.9K Buy
108
+107
+10,700% +$47.4K 0.01% 347
2025
Q3
$456 Hold
1
– – ﹤0.01% 967
2025
Q2
$326 Buy
+1
New +$277 ﹤0.01% 922
2025
Q1
– Sell
-1
Closed -$257 – 1054
2024
Q4
$235 Buy
+1
New +$263 ﹤0.01% 621

Other funds holding ALNY

Activest Wealth Management's ALNY Position: Q3 2026 in Review

Activest Wealth Management reduced its Alnylam Pharmaceuticals (ALNY) stake by 95% in Q3 2026, selling an estimated $5.34K and leaving 1 share worth $247. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Activest Wealth Management first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. The position peaked at $42.9K in Q4 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Activest Wealth Management held 1 share of Alnylam Pharmaceuticals worth $247 as of Q3 2026.
  • Activest Wealth Management sold 21 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $5.34K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #958 holding.
  • Activest Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Activest Wealth Management's Alnylam Pharmaceuticals position peaked at $42.9K in Q4 2025.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.